DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in December

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 194,600 shares, a growth of 28.4% from the November 30th total of 151,500 shares. Based on an average daily volume of 87,500 shares, the short-interest ratio is currently 2.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DMAC. Geode Capital Management LLC lifted its position in shares of DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after acquiring an additional 70,070 shares during the period. Blue Trust Inc. bought a new position in DiaMedica Therapeutics in the third quarter worth $185,000. Magnolia Capital Advisors LLC acquired a new stake in DiaMedica Therapeutics during the second quarter worth $87,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in DiaMedica Therapeutics in the 3rd quarter valued at $40,000. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Price Performance

Shares of DiaMedica Therapeutics stock opened at $5.41 on Friday. The firm has a fifty day moving average price of $4.80 and a two-hundred day moving average price of $4.02. DiaMedica Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $6.41. The company has a market cap of $231.34 million, a PE ratio of -9.66 and a beta of 1.51.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.